Multifunctional nanoplatforms based on RNA interference for glioma treatment.

IF 3.6 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-03-15 eCollection Date: 2025-01-01 DOI:10.62347/AERM5603

Ting Zhao, Hongping Ju, Zihao Chen

{"title":"Multifunctional nanoplatforms based on RNA interference for glioma treatment.","authors":"Ting Zhao, Hongping Ju, Zihao Chen","doi":"10.62347/AERM5603","DOIUrl":null,"url":null,"abstract":"<p><p>Glioma is the most common malignant tumor in the central nervous system. Currently, common clinical treatments for glioma include surgery, radiation therapy, chemotherapy and immunotherapy, among which the combination of chemotherapy and immunotherapy has attracted wide attention. However, the ability of chemotherapeutic agents and immune checkpoint blockers to reach gliomas is limited due to the existence of blood brain/tumor barrier (BBB/BTB). RNA interference (RNAi) technology enables specific silencing of target genes associated with cancer therapy, so it has been used as an emerging potential cancer treatment strategy. However, Small interference RNA (siRNA) is easily degraded by serum endonuclease, which can be quickly filtered and cleared by the glomerulus. Therefore, design and construction of safe and effective delivery systems is conducive to improving the stability of siRNA and the efficiency of gene silencing. This review focuses on the research progress of nano delivery system based on RNA interference for glioma treatment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"835-854"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982710/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/AERM5603","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioma is the most common malignant tumor in the central nervous system. Currently, common clinical treatments for glioma include surgery, radiation therapy, chemotherapy and immunotherapy, among which the combination of chemotherapy and immunotherapy has attracted wide attention. However, the ability of chemotherapeutic agents and immune checkpoint blockers to reach gliomas is limited due to the existence of blood brain/tumor barrier (BBB/BTB). RNA interference (RNAi) technology enables specific silencing of target genes associated with cancer therapy, so it has been used as an emerging potential cancer treatment strategy. However, Small interference RNA (siRNA) is easily degraded by serum endonuclease, which can be quickly filtered and cleared by the glomerulus. Therefore, design and construction of safe and effective delivery systems is conducive to improving the stability of siRNA and the efficiency of gene silencing. This review focuses on the research progress of nano delivery system based on RNA interference for glioma treatment.

查看原文本刊更多论文

基于RNA干扰的多功能纳米平台用于胶质瘤治疗。

神经胶质瘤是中枢神经系统最常见的恶性肿瘤。目前临床上常见的胶质瘤治疗方法包括手术、放疗、化疗和免疫治疗，其中化疗与免疫治疗的结合引起了广泛的关注。然而，由于血脑/肿瘤屏障（BBB/BTB）的存在，化疗药物和免疫检查点阻断剂到达胶质瘤的能力受到限制。RNA干扰（RNAi）技术能够特异性沉默与癌症治疗相关的靶基因，因此它已被用作一种新兴的潜在癌症治疗策略。然而，小干扰RNA （Small interference RNA, siRNA）容易被血清内切酶降解，可被肾小球快速过滤和清除。因此，设计和构建安全有效的递送系统有利于提高siRNA的稳定性和基因沉默的效率。本文综述了基于RNA干扰的纳米递送系统在胶质瘤治疗中的研究进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.